Sera Prognostics (SERA) UBS Genomic Medicine Conference summary

Advances in genetic and proteomic testing for maternal and neonatal care

• Rapid diagnostic genome sequencing and proteomic blood tests are transforming early detection and management of genetic and preterm birth risks, reducing diagnostic odysseys and NICU costs.

• Whole exome and genome sequencing are increasingly used in both outpatient and NICU settings, with growing focus on actionable results and integration with clinical workflows.

• Proteomic screening identifies asymptomatic mothers at risk for preterm birth, offering significant cost savings and improved neonatal outcomes.

Market opportunity, adoption, and barriers

• The inpatient genetic testing market is estimated at $1 billion, but underutilization persists due to workflow and educational barriers.

• Studies show genome sequencing changes management in 85% of NICU cases and could benefit the majority of complex NICU patients.

• Market penetration remains low, with only about 2% of eligible NICU babies currently tested.

• Scaling requires clinician education, updated guidelines, and streamlined ordering, with reimbursement improving as more states and payers cover testing.

Guideline bodies and global trends

• Key guideline bodies include ACMG, AAP, SMFM, and ACOG, with broader adoption hinging on mainstream medical societies endorsing genomic and proteomic testing.

• The UK and other countries are implementing national genome sequencing policies, with similar pilot projects underway globally.